Skip to main content
OpenTrials
Completed

NCT Number: NCT00833001

Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse

The purpose of this study is to evaluate the clinical performance of the PROLIFT system with a new lighter-weight mesh in repair of vaginal prolapse.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Vaginal prolapse (a feeling of bulge in the vagina) may cause some distressing symptoms such as loss of control of the bowel or bladder, and may also cause problems with women's sex life. There are a number of different surgical procedures which are used to repair prolapse. Sometimes a mesh is placed in the pelvis to support the weakened tissues. There is a lot of research going on to find the most suitable type of mesh to repair vaginal prolapse. The GYNECARE PROLIFT + M* Pelvic Floor Repair system is similar to a mesh already used for this procedure called ULTRAPRO*, but is lighter in weight. Currently, ULTRAPRO* is only approved for use in hernia repair and is not licensed for gynecological procedures. This study will be the first clinical investigation of this mesh in vaginal prolapse.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage III or IV, suitable for surgical repair. Perineal repair, vaginal hysterectomy and/or mid urethral sling procedures for incontinence may be performed concurrently.
  • Age > or = 18 years.
  • Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.

Exclusion criteria

  • Additional surgical intervention for POP repair concurrent to the Gynecare Prolift+M procedure (e.g. paravaginal repair, sacrocolpopexy, colporrhaphy in a non-Gynecare Prolift+M treated compartment).
  • Previous repair of pelvic organ prolapse involving insertion of mesh.
  • Previous hysterectomy within 6 months of scheduled surgery.
  • Experimental drug or experimental medical device within 3 months prior to the planned procedure.
  • Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
  • Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
  • History of any pelvic radiation therapy.
  • History of chemotherapy within 6 months of the planned procedure.
  • Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
  • Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
  • Nursing or pregnant or intends future pregnancy.
  • In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.

Treatment and study plan

GYNECARE PROLIFT+M* Pelvic Floor Repair System

Device

Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber

Other names: ULTRAPRO* mesh

Primary outcomes

  1. Pelvic Organ Prolapse Quantification (POP-Q) score

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Summary of treated compartment ICS POP-Q stage

    Time frame: 3, 12, 24 and 36 months

  2. Proportion of subjects with the leading edge within the hymen and without further re-intervention for POP

    Time frame: 12, 24 and 36 months

  3. Incidence of de novo prolapse (a post-operative prolapse)only in the untreated compartment, provided there was no pre-operative defect in that compartment

    Time frame: Procedure to 36 months

  4. Mean scores and change from baseline in PFDI-20 scores, including sub scores (POPDI, CRADI and UDI

    Time frame: 3, 12, 24 and 36 months

  5. Mean scores and change from baseline in PFIQ-7, including sub-scores (POPIQ, CRAIQ and UIQ).

    Time frame: 3, 12, 24 and 36 months

  6. Days to return to normal activities (walking, driving, work, household activities and sexual intercourse)

    Time frame: 1, 3, and 12 months

  7. Assessment of sexual function using PISQ-12 (mean scores and change from baseline) in subjects sexually active at baseline

    Time frame: 12, 24 and 36 months

  8. Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia

    Time frame: Baseline to 36 months

  9. Adverse Events

    Time frame: Procedure to 36 months

  10. Determination of any exposures/erosions including location

    Time frame: Procedure to 36 months

  11. Summary of International Continence Society (ICS) Stages

    Time frame: 3, 24, and 36 months

Sponsors and collaborators

Lead sponsor

Ethicon, Inc.

Industry

Registry information

Official study title

A Prospective, Multi-center Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse

Important dates

Study start
2008
Primary completion
2009
Study completion
2011
First posted
Jan 30, 2009
Registry last updated
May 6, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.